Myeloproliferative neoplasms: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• ABL1 0
• JAK 25
• TP53 1
• PDGFR 0
• STAT3 0
• PI3K 0
• ERK 1
• FGFR 1
• FLT3 3
• mTOR 0
• AKT 0
• BCL-2 2
• IDH 3
• JNK 0
• HIF-1 0
• CSF1R 3
• HSP90 0
• MAPK 0
• MEK 2
• AMPK 0
• CD123 0
• CD19 0
• CD38 0
• IL-6 0
• KMT2A 0
• MDM2 0
• MYC 0
• NRF2 0
• PPAR 0
• RAS 0
• RUNX1 0
• ATM 0
• CD33 1
• CD40 0
• CDK4/6 1
• CXCR4 0
• EZH2 0
• G6PD 0
• HDAC 0
• KRAS 0
• NF1 0
• NLRP3 0
• NOTCH1 0
• NPM1 0
• NTRK 0
• PD-1 0
• PD-L1 0
• SGLT2 0
• SIRT1 0
• YAP 0

24 of 511 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Identification of novel genetic regulators governing leukaemic transformation from myeloid proliferative neoplasms (MPN2AML)

  Medizinische Hochschule Hannover· Hannover, Germany· EU contribution €313,395· until Aug 2029· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Role of CD24 and CD24hi Neutrophils in key co-morbidities associated with the MyeloProliferative Neoplasms (NeutroMPN)

  Universidad de Sevilla· Sevilla, Spain· EU contribution €209,915· until May 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Deciphering fibrosis reversal mechanisms in chronic blood cancer for identification of novel predictive and therapeutic strategies (Rewind-MF)

  Universitaetsklinikum Aachen· Aachen, Germany· EU contribution €1,999,313· until Mar 2029

3 of 3 running projects, newest first. Listed amounts together: €2.5m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

  NCT02530034· M.D. Anderson Cancer Center· Updated 4 Nov 2026

  “FDA Clinical Hold”Registry text, quoted unchanged. Source

• Terminated

  Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

  NCT03627403· University of Utah· Updated 26 Oct 2026

  “PI and Sponsor decision. Accrual was low and there was sufficient data to detect a response.”Registry text, quoted unchanged. Source

• Withdrawn

  A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

  NCT06597734· M.D. Anderson Cancer Center· Updated 5 Oct 2026

  “PI request”Registry text, quoted unchanged. Source

• Terminated

  RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis

  NCT06397313· Ryvu Therapeutics SA· Updated 16 Sept 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Withdrawn

  Pacritinib With Aza for Upfront Myelodysplastic Syndrome

  NCT07387354· Thomas Jefferson University· Updated 17 Aug 2026

  “FDA requested significant changes to the study protocol”Registry text, quoted unchanged. Source

• Withdrawn

  Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera

  NCT06290765· PharmaEssentia· Updated 31 Jul 2026

  “In alignment with company strategic direction.”Registry text, quoted unchanged. Source

• Terminated

  Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

  NCT01962636· Masonic Cancer Center, University of Minnesota· Updated 20 May 2026

  “No longer a research question to answer.”Registry text, quoted unchanged. Source

• Terminated

  Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

  NCT03246906· Fred Hutchinson Cancer Center· Updated 14 May 2026

  “Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and Data Safety Monitoring Board recommendations.”Registry text, quoted unchanged. Source

• Terminated

  Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

  NCT03878199· Ohio State University Comprehensive Cancer Center· Updated 24 Apr 2026

  “The study was originally planned to assess four escalating DLs of ruxolitinib (upto 40 mg twice daily), but was closed early due to slow enrollment and changing treatment landscape moving towards less intense approaches.”Registry text, quoted unchanged. Source

• Withdrawn

  Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

  NCT06284460· M.D. Anderson Cancer Center· Updated 13 Feb 2026

  “Drug Source Request”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

  NCT04446650· Bristol-Myers Squibb· Source

• Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

  NCT06303193· National Cancer Institute (NCI)· Source

• A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

  NCT06351631· Merck Sharp & Dohme LLC· Source

• A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Novartis Pharmaceuticals· Source

• Asciminib Roll-over Study

  NCT04877522· Novartis Pharmaceuticals· Source

• Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  NCT05554406· National Cancer Institute (NCI)· Source

• A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Takeda· Source

• A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Incyte Corporation· Source

• A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).

  NCT07722611· Merck Sharp & Dohme LLC· Source

• A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

  NCT06150157· Janssen Research & Development, LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 8
• Organoids 1
• Mendelian Randomization Analysis 1
• CRISPR-Cas Systems 2
• Gene Expression Profiling 14
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 2
• Exome Sequencing 4
• Proteomics 7
• Metabolomics 3
• Mass Spectrometry 2
• Flow Cytometry 19
• Immunohistochemistry 2
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 22
• Magnetic Resonance Imaging 14
• Machine Learning 7
• Deep Learning 3
• Cohort Studies 16
• Genome-Wide Association Study 1

• Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis.

  Cancer Discov, Sept 2026

• The molecular management of classic myeloproliferative neoplasm.

  J Egypt Natl Canc Inst, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.